Norditropin Daily denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare requires prior authorization for Norditropin (daily somatropin) under its Commercial growth hormone policy, and defines an "essential" use of growth hormone as therapy to treat a deficiency as part of chronic disease management, distinguishing it from non-essential replacement uses . Covered indications follow FDA labeling and include Congenital Growth Hormone Deficiency (GHD), Pediatric GHD, Transition Phase Adolescent GHD, Adult GHD, and Prader-Willi Syndrome , with additional pediatric indications such as short stature born small for gestational age (SGA) with no catch-up growth by age 2 to 4, and Idiopathic Short Stature (ISS) with height SDS less than -2.25 and growth rates unlikely to permit attainment of adult height in the normal range . Authorization is issued for 12 months at a time , and for transition adolescents the criteria apply during the period from mid to late teens until 6 to 7 years after achievement of adult height . Contraindications per labeling include acute critical illness after open heart or abdominal surgery or multiple accidental trauma, pediatric patients with Prader-Willi syndrome who are severely obese or have upper airway obstruction/sleep apnea, hypersensitivity to somatropin or excipients, and active proliferative or severe non-proliferative diabetic retinopathy . Benefit caps may apply: if the diagnosis is essential the cap is overridden, but if non-essential only the authorization applies and supply limits may be in place . Adult GHD diagnosis typically requires biochemical confirmation (e.g., Insulin Tolerance Test less than 5 ng/mL as the test of choice ) and an endocrinologist must coordinate therapy.

- Submit complete biochemical workup: two failed GH provocative stimulation tests for pediatric GHD per Pediatric Endocrine Society (Grimberg et al., 2016) guidelines, or for adults the Endocrine Society 2011 guideline (Molitch et al.) and AACE/ACE 2019 guideline ( College of endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care, Endocr Pract 2019;25(11):1191-1232 ) which support diagnosis with documented pituitary/hypothalamic disease plus low IGF-1 - Provide growth charts demonstrating height SDS and growth velocity, citing Pediatric Endocrine Society guidelines providing recommendations for the clinical management of children and adolescents with growth failure ; if transition-age, cite AACE 2019 transition guidance for retesting - Document open epiphyses by X-ray and ongoing growth velocity >2 cm/year, or document clinical reason for slower response (e.g., late puberty), aligned with Pediatric Endocrine Society recommendations - Confirm prescription is written or co-managed by a board-certified endocrinologist with attestation letter - Demonstrate that contraindications do not apply (e.g., negative sleep study and BMI documentation for PWS patients, ophthalmologic clearance for diabetics, no active neoplasm) per Norditropin prescribing information - Argue essential-use designation: GHD as replacement for a chronic pituitary disease meets UHC's own definition of "therapy to treat a deficiency as part of chronic disease management" , which should override benefit caps - For adult continuation, submit IGF-1 normalization, improvement in body composition, lipid profile, and quality-of-life scores (AGHDA) supporting clinical benefit per Endocrine Society guideline ( Molitch ME et al., Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab )

## Why UnitedHealthcare Flagged Norditropin as Duplicate Therapy

A duplicate-therapy denial on Norditropin from UnitedHealthcare almost never means the clinical indication is in dispute — it means UHC's claims engine (or OptumRx's adjudication system, depending on whether the script routed through the medical or pharmacy benefit) saw an overlapping paid claim for another somatropin product or a long-acting GH analog within the patient's recent fill history. Common triggers under the Human Growth Hormone – Somatropin Commercial Medical Benefit Drug Policy: an unexpired authorization for Genotropin, Humatrope, Nutropin AQ, Omnitrope, Saizen, or Zomacton; concurrent days-of-supply with the long-acting agents Sogroya (somapacitan), Skytrofa (lonapegsomatropin-tcgd), or Ngenla (somatrogon-ghla); or an active Increlex (mecasermin) claim. UHC treats the entire somatropin class as therapeutically interchangeable for duplicate-therapy edits even though the FDA labels and pen devices differ.

## The Procedural Channel Matters

Norditropin is almost always dispensed through Optum Specialty Pharmacy (formerly BriovaRx), not retail. That means the denial letter you received likely came from OptumRx under the pharmacy benefit even though the underlying clinical policy is a medical benefit drug policy. Appeal to the wrong channel and the clock keeps running. Confirm the denial source on the EOB — if the claim adjudicated under Rx BIN 610279/610593 it is OptumRx; if it adjudicated under the medical benefit it is UHC clinical review (often routed to Optum's clinical pharmacist team). The reconsideration form and fax number are different. Under 29 CFR §2560.503-1(g), UHC must provide on request the specific overlapping claim, paid date, dispensing pharmacy, and NDC that triggered the duplicate-therapy edit — demand this in writing before drafting the medical necessity letter, because the appeal has to rebut the specific overlap, not the abstract concept.

## Rebuilding the Record

The winning appeal package addresses the overlap directly: a prescribing endocrinologist attestation (the policy requires endocrinologist coordination) stating (1) the exact discontinuation date of the prior somatropin product, (2) the clinical reason for the switch — device intolerance, injection-site reactions, pen dosing granularity for pediatric titration, formulary movement, or supply disruption — and (3) confirmation that doses are not being stacked. Attach the discontinuation note from the chart and, if available, a pharmacy return/destruction record. Cite the 12-month authorization framework in the policy and request the new auth supersede the prior one. For Adult GHD switches, re-confirm biochemical diagnosis (ITT <5 ng/mL or glucagon stim).

## Tactical Tip

If the overlap is an artifact of a 30-day stockpile from the prior brand, ask Optum Specialty to cancel and reverse the prior fill rather than appealing — a reversal removes the duplicate flag instantly and the new PA can be reprocessed same-day. If reversal is refused, escalate to the UHC Provider Advocate for the prescriber's TIN and, for fully-insured plans, file a parallel complaint with the state Department of Insurance; for ERISA self-funded plans cite Pinto v. Aetna (10th Cir. 2014) to shift the experimental/duplicative burden of proof back to the plan administrator.